BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9169646)

  • 1. Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants.
    Al-Fiar FZ; Colwill R; Lipton JH; Fyles G; Spaner D; Messner H
    Bone Marrow Transplant; 1997 May; 19(10):1019-22. PubMed ID: 9169646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation.
    Boulad F; Bromley M; Black P; Heller G; Sarafoglou K; Gillio A; Papadopoulos E; Sklar C
    Bone Marrow Transplant; 1995 Jan; 15(1):71-6. PubMed ID: 7742758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid dysfunction following bone marrow transplantation: long-term follow-up of 80 pediatric patients.
    Katsanis E; Shapiro RS; Robison LL; Haake RJ; Kim T; Pescovitz OH; Ramsay NK
    Bone Marrow Transplant; 1990 May; 5(5):335-40. PubMed ID: 2350628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of allogeneic bone marrow transplantation (BMT) on pituitary, gonad, thyroid and adrenal function in adults.
    Kauppila M; Koskinen P; Irjala K; Remes K; Viikari J
    Bone Marrow Transplant; 1998 Aug; 22(4):331-7. PubMed ID: 9722067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid function in children after allogeneic bone marrow transplantation.
    Borgström B; Bolme P
    Bone Marrow Transplant; 1994 Jan; 13(1):59-64. PubMed ID: 8019454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid dysfunction after bone marrow transplantation for primary immunodeficiency without the use of total body irradiation in conditioning.
    Slatter MA; Gennery AR; Cheetham TD; Bhattacharya A; Crooks BN; Flood TJ; Cant AJ; Abinun M
    Bone Marrow Transplant; 2004 May; 33(9):949-53. PubMed ID: 15004542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases.
    Tauchmanovà L; Selleri C; Rosa GD; Pagano L; Orio F; Lombardi G; Rotoli B; Colao A
    Cancer; 2002 Sep; 95(5):1076-84. PubMed ID: 12209694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
    Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preparatory regimen of total body irradiation, busulphan and melphalan for allogeneic bone marrow transplantation in childhood high-risk leukemia and lymphoma.
    Yoshihara T; Naya M; Tsunamoto K; Hojo M; Hibi S; Morimoto A; Todo S; Imashuku S
    Anticancer Res; 2003; 23(2C):1739-42. PubMed ID: 12820450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
    Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Health status and late complications following allogeneic bone marrow transplantation. A review].
    Tichelli A; Gratwohl A; Uhr M; Dazzi H; Hoffmann T; Stebler Gysi C; Walther E; Roth J; Hünig R; Nissen C
    Schweiz Med Wochenschr; 1991 Oct; 121(41):1473-81. PubMed ID: 1947943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans.
    Kerbauy FR; Tirapelli B; Akabane H; Oliveira JS
    Bone Marrow Transplant; 2009 Jun; 43(11):883-5. PubMed ID: 19079309
    [No Abstract]   [Full Text] [Related]  

  • 15. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged >or=50 years compared to younger adults with low-risk disease.
    Farag SS; Elder PJ; Marcucci G; Penza S; Mrozek E; Molina A; Lin T; Avalos BR; Copelan E
    Bone Marrow Transplant; 2003 Jan; 31(2):87-93. PubMed ID: 12621488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
    Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
    Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
    Bertz H; Potthoff K; Mertelsmann R; Finke J
    Bone Marrow Transplant; 1997 Jun; 19(12):1169-73. PubMed ID: 9208109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor.
    Kanda Y; Sakamaki H; Sao H; Okamoto S; Kodera Y; Tanosaki R; Kasai M; Hiraoka A; Takahashi S; Miyawaki S; Kawase T; Morishima Y; Kato S;
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):881-9. PubMed ID: 16275591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.